title: Cancer nanotherapeutics in clinical trials.
abstract: To be legally sold in the United States, all drugs must go through the FDA approval process. This chapter introduces the FDA approval process and describes the clinical trials required for a drug to gain approval. We then look at the different cancer nanotherapeutics and in vivo diagnostics that are currently in clinical trials or have already received approval. These nanotechnologies are catagorized and described based on the delivery vehicle: liposomes, polymer micelles, albumin-bound chemotherapeutics, polymer-bound chemotherapeutics, and inorganic particles.
authors.affiliation: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
authors.forename: Abigail K R
authors.initials: AK
authors.lastname: Lytton-Jean
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Kauffman
authors.forename: James C
authors.initials: JC
authors.lastname: Kaczmarek
authors.forename: Robert
authors.initials: R
authors.lastname: Langer
mesh_terms: D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D050997:Nanomedicine / Q000331:legislation & jurisprudence* / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration